Novartis (NVS) suspended eight clinical trials of an experimental CAR-T cell therapy for autoimmune and neurological diseases in late August after three patients died from severe immune responses, raising fresh questions about the durability of the company’s next-generation pipeline.
For long-horizon investors banking on Novartis expanding beyond its core immunology and oncology franchises, the halt signals meaningful regulatory and clinical risk in what had been one of the sector’s most-watched growth corridors. 1
Key Takeaways
- Eight Novartis CAR-T autoimmune trials paused after three fatal immune reactions.
- Bristol-Myers Squibb also halted comparable CAR-T autoimmune studies.
- Novartis calls fatal immune response a known, class-wide CAR-T safety risk.
Market Context & Peer Impact
The simultaneous pause at Bristol-Myers Squibb (BMY) – which separately suspended its own CAR-T autoimmune trials as a precautionary measure – underscores that this is a class-level concern rather than an isolated Novartis manufacturing or protocol failure. 2 That distinction matters: a company-specific issue would be more readily remedied, while a class-wide signal could set back the entire field’s timeline and force regulators to impose broader restrictions before pivotal trials can resume.
CAR-T therapies already carry established safety warnings in oncology settings. Their application to autoimmune and neurological disease – a far larger addressable market – had been touted by Novartis and peers as a potential multi-billion-dollar revenue opportunity beyond cancer.
Detailed Analysis
The experimental treatment works by extracting a patient’s T-cells, genetically modifying them to recognize a specific biological target, and reinfusing them to attack disease-driving immune cells – the same mechanism used in approved cancer CAR-T products such as Novartis’s own Kymriah. 1 Adapting the approach for autoimmune conditions like lupus or multiple sclerosis had generated significant clinical excitement, with early data showing deep and durable remissions in small patient cohorts.
However, the three deaths attributed to a severe immune response – a reaction type physicians call cytokine release syndrome or similar immune-mediated toxicity – illustrate that the safety profile established in cancer patients may not translate cleanly to a population with different baseline immune function. The company said it is conducting “a comprehensive review of the observed safety events,” characterizing the fatal response as a known safety risk in CAR-T therapies. 2
Novartis said it is working with independent safety monitoring boards overseeing each paused study and sharing findings with regulators. It was not immediately clear precisely when the three deaths occurred within the late-August window. The autoimmune CAR-T space has drawn growing attention from investors tracking the broader expansion of autoimmune therapies, a segment where multiple drugmakers are competing for first-mover advantage.
Outlook & Management Quote
A Novartis spokesman said the company is conducting
“a comprehensive review of the observed safety events,”
describing the immune reaction as a known hazard within the CAR-T class rather than an unexpected new phenomenon. 2 That framing may limit immediate reputational damage but does little to accelerate the timeline for resuming trials, which will depend on the findings of safety boards and regulatory guidance.
Neither Novartis nor Bristol-Myers Squibb responded to Reuters requests for comment as of publication. The duration of the holds and the conditions under which trials might restart remain undefined. 2
Conclusion
For investors with multi-year horizons, the core question is whether the autoimmune CAR-T thesis is delayed or derailed. A temporary hold pending a protocol amendment would represent a setback of months; a finding that immune-mediated fatalities are intrinsic to the mechanism in non-oncology populations could force a fundamental redesign of the approach or narrow its viable patient population significantly. Until safety reviews conclude, the revenue contribution these programs were expected to generate beyond 2028 must be treated as highly uncertain.
Not investment advice. For informational purposes only.
References
1(2026-09-01). “Novartis Pauses Autoimmune Cell Therapy Studies After Deaths”. The Wall Street Journal. Retrieved September 1, 2026.
2Shivani Tanna (2026-09-01). “Novartis pauses autoimmune cell therapy studies after deaths, WSJ reports”. Reuters via KFGO. Retrieved September 1, 2026.